Clinical Trial. U.S. to Tell Drug Makers to Disclose Payments to Doctors. Institute For The Future. Cancer treatment. Health & Medicine. Biotech Firms Caught In Regulatory No Man's Land. Hide caption AquaBounty's genetically modified salmon is seen swimming behind a much smaller wild Atlantic salmon of the same age. AquaBounty has been trying to get government approval to sell its salmon for more than a decade. Courtesy of AquaBounty Technologies Companies making genetically modified animals face a regulatory morass in this country. It's not always clear which federal agency has responsibility for regulating a particular animal, and even when one agency does take the lead, the approval process can drag on for years.
The companies say this uncertainty means their technologies may die without ever being given a chance. Take the case of the British company Oxitec. Dengue is potentially fatal, and there is no treatment or vaccine. Luke Alphey, chief scientific officer of Oxitec, says the basic idea is very simple. "Over time, with periodic releases or successive releases of these sterile males, the target population will collapse," says Alphey. No mosquitoes, no dengue. CureTogether. 研究資料：Freedom to Patients 〜患者視点の医療政策を考える会〜
VRX:Toronto Stock Quote - Valeant Pharmaceuticals International Inc. Recently Viewed Symbols Key Statistics for VRX mrq = Most Recent Quarter; ttm = Trailing Twelve Months Income Statement for VRX Revenue Net Income (M/USD) Profit Margin (%) Company Profile & Key Executives for VRX Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders, and distributes generic and branded generic drugs in Latin America and Eastern Europe. More Company Profile & Key Executives for VRX Quotes delayed, except where indicated otherwise.